Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Lee E, Burgess K · Alternative Therapies in Health and Medicine

The entire published human safety dataset for systemic BPC-157: across cardiac, renal and liver panels over three days the authors report no adverse effect. Creatine kinase and B-type natriuretic peptide stayed inside reference range in both. One renal signal did move — the woman's creatinine went from 0.6 to 0.9 and back to 0.6, with eGFR 106, then 66, then 106 — which the authors attribute to likely dehydration on the morning of the second draw, reasoning that a dose-dependent injury would have worsened after the larger second dose rather than resolving.

Population

Two adults without acute pain or musculoskeletal injury, aged 58 and 68 — a woman with thalassemia taking oral progesterone and transdermal estradiol, and a man on no medication. Chronic kidney disease, diabetes, hypothyroidism, liver failure, pregnancy and heart conditions were exclusions

Intervention

IV BPC-157, 10 mg in 250 cc of saline over an hour on day 1 and 20 mg the same way on day 2, from a 503A compounding pharmacy the paper does not name

Comparator

None

Limitations

Two people, a 48-hour exposure and a third-day draw, no control, no blinding, and nothing about repeated or longer dosing. Both participants paid the roughly $1,000 cost themselves and, by the paper's own account, volunteered in order to demonstrate the peptide's safety so that compounding pharmacies might be allowed to make it, so the subjects were not disinterested. The supplying pharmacy is unnamed. The authors declare no conflict of interest and no funding; the study was run at the first author's own Institute for Hormonal Balance.